Peter Öhman

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Juan P. Frías, Cristian Guja, Elise Hardy et al. · The Lancet Diabetes & Endocrinology · 2016 · 389 citations

Medicine, Internal Medicine, Pharmacotherapy +16

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Medicine, Cardiology, Pharmacotherapy +17

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M. Angelyn Bethel, Robert J. Mentz, Peter Merrill et al. · Diabetes Care · 2019 · 117 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17